BridgeBio Oncology Therapeutics, Inc. - 8-K Filing

Yong Ben, M.D., M.B.A. to resign as Chief Medical and Development Officer effective January 8, 2027 (Items: 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offic)

SEC EDGAR ·

Tickers: $BBOT

Read the full article at SEC EDGAR

More Regulatory news